156 related articles for article (PubMed ID: 23777683)
1. Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data.
Picón T; Alonso L; García Gabarrot G; Speranza N; Casas M; Arrieta F; Camou T; Rosa R; De Oliveira LH; Verani JR
Vaccine; 2013 Jul; 31 Suppl 3():C109-13. PubMed ID: 23777683
[TBL] [Abstract][Full Text] [Related]
2. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
Ingels HA
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.
Jayasinghe S; Chiu C; Quinn H; Menzies R; Gilmour R; McIntyre P
Clin Infect Dis; 2018 Jul; 67(3):367-374. PubMed ID: 29471432
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
5. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
García Gabarrot G; López Vega M; Pérez Giffoni G; Hernández S; Cardinal P; Félix V; Gabastou JM; Camou T;
PLoS One; 2014; 9(11):e112337. PubMed ID: 25375647
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Naidoo N; Meiring S; Quan V; Nokeri V; Fortuin-de Smit M; Malope-Kgokong B; Moore D; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Kularatne R; Conklin L; O'Brien KL; Zell ER; Klugman K; Whitney CG; von Gottberg A;
Clin Infect Dis; 2014 Sep; 59(6):808-18. PubMed ID: 24917657
[TBL] [Abstract][Full Text] [Related]
7. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
9. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
[TBL] [Abstract][Full Text] [Related]
11. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
13. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
[TBL] [Abstract][Full Text] [Related]
14. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.
De Serres G; Pilishvili T; Link-Gelles R; Reingold A; Gershman K; Petit S; Farley MM; Harrison LH; Lynfield R; Bennett NM; Baumbach J; Thomas A; Schaffner W; Beall B; Whitney C; Moore M
Vaccine; 2012 Jun; 30(27):4067-72. PubMed ID: 22525797
[TBL] [Abstract][Full Text] [Related]
15. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
17. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
[TBL] [Abstract][Full Text] [Related]
18. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
20. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
